Eli Lilly and Company ($LLY) Stock Forecast: Up 5.2% Today

What is Eli Lilly and Company?

Eli Lilly (LLY) is a pharmaceutical company known for its innovative drug developments in various therapeutic areas. Today, the stock experienced a strong bullish movement in the market.

Why is Eli Lilly and Company going up?

LLY stock is up 5.2% on Nov 20, 2024 15:01

• Eli Lilly's stock surged after announcing positive Phase 2 results for muvalaplin, an investigational drug that showed promising efficacy in reducing sticky cholesterol levels by almost 86%.
• Investor sentiment was further boosted by a notable endorsement on a financial media show, where the recommendation to buy Eli Lilly stock was made, citing its potential despite being previously unpopular.
• The detailed Phase 3 data release showing impressive results from a study of tirzepatide also contributed to the positive market response, indicating strong growth prospects for Eli Lilly in the pharmaceutical sector.

LLY Price Chart

LLY Technical Analysis

LLY News

The Zacks Analyst Blog Highlights Eli Lilly, PepsiCo and Morgan Stanley

Eli Lilly, PepsiCo and Morgan Stanley are included in this Analyst Blog.

https://www.zacks.com/stock/news/2372497/the-zacks-analyst-blog-highlights-eli-lilly-pepsico-and-morgan-stanley

Top Research Reports for Eli Lilly, PepsiCo & Morgan Stanley

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), PepsiCo, Inc. (PEP) and Morgan Stanley (MS).

https://www.zacks.com/research-daily/2371997/top-research-reports-for-eli-lilly-pepsico-morgan-stanley

Eli Lilly's Investigational Drug Cuts Sticky Cholesterol Levels By Almost 86% - Eli Lilly ( NYSE:LLY )

On Monday, Eli Lilly And Co LLY announced Phase 2 results for muvalaplin, an investigational once-daily, orally administered selective inhibitor of lipoprotein ( a ) [Lp ( a ) ], a genetically inherited risk factor for heart disease.

https://www.benzinga.com/24/11/42070751/eli-lillys-investigational-drug-cuts-sticky-cholesterol-levels-by-almost-86

Jim Cramer: Coinbase Is A 'Winner,' Suggests Buying This 'Hated' Big Pharma Stock - Eli Lilly ( NYSE:LLY )

On CNBC's "Mad Money Lightning Round," Jim Cramer said Eli Lilly LLY is a buy. "This stock is as hated now as it was loved not that long ago," he added. Eli Lilly on Monday said Muvalaplin met secondary endpoints for all three tested doses. Coinbase Global, Inc. COIN is a "winner," Cramer said.

https://www.benzinga.com/trading-ideas/long-ideas/24/11/42068776/jim-cramer-coinbase-is-a-winner-suggests-buying-this-hated-big-pharma-stock

99% Of Mounjaro/Zepbound Patients Remained Diabetes-Free Even At 3 Years, Eli Lilly's Detailed Phase 3 Data Shows - Eli Lilly ( NYSE:LLY )

On Wednesday, Eli Lilly And Co LLY released detailed results from the Phase 3 SURMOUNT-1 three-year study ( 176-week treatment period ) , the longest completed study to date of tirzepatide.

https://www.benzinga.com/24/11/41985752/eli-lillys-detailed-phase-3-trial-data-show-99-of-patients-on-popular-mounjarozepbound-remained-diabetes-free-for

Trending Today

XRP ($XRP) Crypto Forecast: Up 25.8% Today

Pepe ($PEPE) Crypto Forecast: Up 9.8% Today

Cardano ($ADA) Crypto Forecast: Up 11.2% Today

Stellar ($XLM) Crypto Forecast: Up 16.7% Today

Avalanche ($AVAX) Crypto Forecast: Up 5.7% Today

Solana ($SOL) Crypto Forecast: Up 7.5% Today

Starknet ($STRK) Crypto Forecast: Up 11.6% Today

Lido DAO ($LDO) Crypto Forecast: Up 8.2% Today

Ethena ($ENA) Crypto Forecast: Up 13.9% Today

Ethereum ($ETH) Crypto Forecast: Up 7.5% Today

Eli Lilly and Company Price History

30.09.2024 - LLY Stock was down 8.2%

• Disappointing third-quarter earnings and sales were reported by Eli Lilly, missing estimates for both metrics.
• Sales of key products such as Mounjaro and Zepbound also fell below expectations, contributing to the stock's decline.
• The company's lowered 2024 guidance and the significant hit to profit further fueled negative sentiment among investors, leading to an 11% decline in the stock.
• The market reaction indicates that investors were not pleased with the company's performance and outlook, causing a sharp decline in the stock price.

30.09.2024 - LLY Stock was down 13.6%

• Eli Lilly (LLY) reported Q3 earnings and revenue below estimates, leading to a -22.37% surprise in earnings and a 4.92% miss in revenue.
• The company's third-quarter earnings were impacted by a more than double increase in Mounjaro sales but took a $2.98 billion hit to profit, causing the stock to plummet.
• Despite an impressive 51% year-to-date gain, speculation around a stock split, and focus on tirzepatide medicines like Mounjaro and Zepbound, the missed revenue consensus and lowered annual outlook contributed to the bearish movement.
• Additionally, the release of new data on donanemab potentially providing a path to improved profiles might not have been enough to offset the negative impact of the earnings miss and lowered guidance.

15.10.2024 - LLY Stock was down 5.7%

• Detailed results from the Phase 3 SURMOUNT-1 three-year study for tirzepatide led to investor disappointment, influencing the bearish sentiment towards Eli Lilly.
• Unusual options activity from substantial investors indicated a bearish stance, potentially contributing to the stock's decline.
• Criticism from a humanitarian organization about high insulin prices by insulin manufacturers, including Eli Lilly, raised concerns about regulatory challenges or public backlash.
• Despite weaker sales of Mounjaro and Zepbound in the third quarter, growth opportunities for Eli Lilly suggest that the current bearish movement may be a temporary market reaction rather than a long-term trend.

08.10.2024 - LLY Stock was up 5.1%

• Market whales making bullish bets on LLY options indicate confidence in the company's future prospects.
• The positive sentiment towards high-growth stocks may have spilled over to Eli Lilly, contributing to its bullish movement.
• Analysts assessing Eli Lilly's performance against competitors in the pharmaceutical industry might have highlighted its strengths, boosting investor confidence.
• Overall, the combination of bullish options activity, positive market sentiment, and favorable industry comparisons likely propelled Eli Lilly's stock to a strong bullish movement today.

31.09.2024 - LLY Stock was up 7.0%

• Despite missing Q3 earnings and revenue estimates, Eli Lilly's stock saw a strong bullish movement, showcasing resilience in the market.
• The bearish movement caused by the company cutting its 2024 forecast was overshadowed by the positive market sentiment towards the pharmaceutical industry as a whole.
• Investors may be focusing on the company's impressive year-to-date gain and potential stock split speculation, leading to increased buying interest despite the recent setbacks in earnings and guidance.
• The overall bullish market movement and positive sentiment towards pharmaceutical companies could have contributed to Eli Lilly's stock outperforming expectations today.

31.09.2024 - LLY Stock was up 6.9%

• Despite missing Q3 earnings and revenue estimates, Eli Lilly's stock saw a strong bullish movement, showcasing resilience in the face of disappointing financial results.
• The market may have reacted positively due to the anticipation of a potential stock split, fueled by the company's impressive 51% year-to-date gain.
• The overall bullish market movement could be attributed to investors focusing on the long-term growth prospects of Eli Lilly, overlooking the short-term setbacks in the quarterly results.
• It's possible that investors are optimistic about the future pipeline of drugs and treatments from Eli Lilly, leading to increased confidence in the company's ability to rebound from the recent financial challenges.

20.10.2024 - LLY Stock was up 5.2%

• Eli Lilly's stock surged after announcing positive Phase 2 results for muvalaplin, an investigational drug that showed promising efficacy in reducing sticky cholesterol levels by almost 86%.
• Investor sentiment was further boosted by a notable endorsement on a financial media show, where the recommendation to buy Eli Lilly stock was made, citing its potential despite being previously unpopular.
• The detailed Phase 3 data release showing impressive results from a study of tirzepatide also contributed to the positive market response, indicating strong growth prospects for Eli Lilly in the pharmaceutical sector.

09.07.2024 - LLY Stock was up 7.7%

• Despite a generally cautious market sentiment with US stocks slipping slightly, Eli Lilly's stock stood out with a bullish movement.
• Unusual options activity indicating a bullish stance on Eli Lilly might have contributed to the stock's upward momentum.
• Eli Lilly's impressive $4B earnings in the second quarter, driven by successful drugs like Zepbound, likely boosted investor confidence and contributed to the bullish trend.
• The positive market response to Eli Lilly's improved profit forecast, amidst a broader market rally fueled by better-than-expected jobless data, further propelled the stock upwards.

09.07.2024 - LLY Stock was up 5.5%

• Strong earnings for the second quarter boosted Eli Lilly's stock, signaling a positive outlook for performance and growth.
• Investor interest in the healthcare sector, which includes Eli Lilly, has been growing as capital flows from high-growth and tech stocks to more stable industries during market uncertainties.
• The confidence in Eli Lilly's stock may stem from investors turning to healthcare investments for their resilience and consistent demand, irrespective of economic fluctuations.
• Despite concerns about healthcare sector valuations and potential regulatory changes post the upcoming presidential election, Eli Lilly's robust earnings report appears to have overshadowed these apprehensions and contributed to the stock's bullish trend.

09.07.2024 - LLY Stock was up 5.1%

• Eli Lilly (LLY) experienced a bullish trend today as unusual options activity suggested a positive outlook from investors.
• The healthcare sector, including pharmaceutical companies like Eli Lilly, is benefitting from a market rotation where traders are reallocating capital from aggressive growth and tech stocks to safer sectors like healthcare.
• The upcoming presidential election and potential regulatory changes in the healthcare industry may be attracting investors towards established healthcare companies like Eli Lilly.
• Despite concerns about overvaluation in the healthcare sector, Eli Lilly's robust performance in the second quarter, particularly with diabetes and weight drugs, likely contributed to the optimistic market sentiment surrounding the stock.

09.07.2024 - LLY Stock was up 6.1%

• Eli Lilly reported impressive earnings of $4 billion in the second quarter, surpassing Wall Street expectations, particularly driven by the success of newer drugs like Zepbound in the diabetes and weight management segment.
• The overall market sentiment was positive, with the Nasdaq and S&P 500 both ending over 2% higher following better-than-expected jobless data, alleviating concerns about the labor market and boosting investor confidence.
• Analysts and experts have highlighted Eli Lilly as a standout in the pharmaceutical industry, with the company leading the way in its business segment, contributing to the stock's significant surge.
• The focus on innovative drugs for prevalent health issues like obesity has positioned Eli Lilly favorably, especially as the global obesity epidemic continues to grow, attracting investors and driving the stock's best trading day in a year.

08.07.2024 - LLY Stock was up 11.1%

• Eli Lilly reported strong earnings that surpassed expectations, leading to an 8% increase in its stock price.
• Investor concerns about the stock were eased by the positive earnings, supporting the upward movement.
• The positive news about weekly jobless claims also contributed to the overall positive sentiment in the market, benefiting stocks like Eli Lilly.
• The company's impressive performance reassured analysts and investors, indicating growing confidence in its future growth and market position.